The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing technologies and (potentially) the whole field of microbiome-targeted therapies. Based in Research Triangle Park, N.C., Locus is commercializing research initially developed by scientists at […]
View More Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapiesCategory: Synthego
8VC has closed its second early-stage fund, seemingly with an eye on logistics and biotech
8VC, the early-stage, San Francisco-based venture firm founded in 2015 by serial entrepreneur Joe Lonsdale and four other general partners, has closed it second early-stage venture fund with $640 million in commitments, says one of its investors. The fund comes roughly two years after the firm closed its debut fund with $425 million, along with a […]
View More 8VC has closed its second early-stage fund, seemingly with an eye on logistics and biotech